PREFERE-the German prostatic cancer study: Questions and claims surrounding study initiation in January 2013;PREFERE-die Deutsche Prostatakrebsstudie: Fragen und Behauptungen rund um den Studienbeginn im Januar 2013

Urologe - Ausgabe A

Volumn 52, Issue 4, 2013, Pages 576-579

  Wiegel, T ^a   Albers, P ^b   Bussar Maatz, R ^c   Gottberg, A ^d   Harter M ^e   Kieser, M ^f   Kristiansen, G ^g   Nettekoven, G ^h   Martus, P ⁱ   Schmidberger, H ^j   Wellek, S ^k   Stockle M ^l  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Deutsche Krebsgesellschaft   (Germany)

^d GKV Spitzenverband   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h Deutsche Krebshilfe e V   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

Prostatic cancer; Randomized trial; Treatment options

Indexed keywords

CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; GERMANY; HUMAN; MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT PLANNING;

BRACHYTHERAPY; GERMANY; HUMANS; MALE; PREVALENCE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 84879917156     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-013-3186-5     Document Type: Review

References (8)

1. Ulm K (2013) Kommentar aus Sicht der Statistik. Uro-News 17(1):14-15
2. Porzsolt F (2013) Interview "Keine präferenz-, sondern exklusionsbasierte Studie". Monitor Versorgungsforschung 2013(1):16-17
3. Andriole GL, Crawford ED, Grubb RL et al (2009) Mortality results from a randomized prostata-cancer screening trial. N Engl J Med 360(13):1310-1319
4. Andriole GL, Crawford ED, Grubb RL et al (2012) Prostata cancer screening in the randomized prostata, lung, colorectal, and ovarian cancer screening trial: mortality results. J Natl Cancer Inst 104(2):125-132
5. Schröder FH, Hugosson J, Roobol MJ et al (2012) Prostata cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981-990
6. Wilt TJ, Jones KM, Barry MJ et al (2012) Prostata Cancer Intervention Versus Observation Trial (Pivot) Study Group. N Engl J Med 367(3):203-213
7. Deutsche Gesellschaft für Urologie, Arbeitsgemeinschaft für Urologische Onkologie der Deutschen Krebsgesellschaft (2012) Stellungnahme zur PIVOT-Studie und der Frage unnötiger Operationen bei Prostatakrebs (Stellungnahme v. 2.8.2012) Stellungnahme DGU betreff PIVOT. DGU, Berlin
8. King M et al (2005) Impact of participant and physician intervention preferences on randomized trials. JAMA 293(9):1089-1099